Rilzabrutinib

Moderate

Rilzabrutinib Dasatinib Phyrago Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Rilzabrutinib Deflazacort Emflaza Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Rilzabrutinib Deuruxolitinib Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Rilzabrutinib Diazepam Nasal Spray Valtoco Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Rilzabrutinib Diazepam Rectal Diastat Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Rilzabrutinib Digoxin Cardoxin® Increased digoxin exposure and an increased risk of digoxin-related adverse reactions Details Rilzabrutinib Dihydroergotamine Injection DHE-45® Injection Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Rilzabrutinib Dihydroergotamine Nasal Spray Migranal Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Rilzabrutinib Docetaxel Beizray Increased CYP3A substrate/OATP1B exposure and an increased risk of CYP3A4/OATP1B substrate-related adverse reactions Details Rilzabrutinib Docetaxel Injection Beizray Increased CYP3A substrate/OATP1B exposure and an increased risk of CYP3A4/OATP1B substrate-related adverse reactions Details Rilzabrutinib Dofetilide Tikosyn Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Rilzabrutinib Dolutegravir Juluca® (as a combination product containing dolutegravir, rilpivirine) Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Rilzabrutinib Doravirine Pifeltro Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Rilzabrutinib Elacestrant Orserdu Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Rilzabrutinib Entrectinib Rozlytrek Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Rilzabrutinib Eravacycline Injection Xerava Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Rilzabrutinib Erdafitinib Balversa Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Rilzabrutinib Estradiol Delestrogen Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Rilzabrutinib Estradiol Topical Divigel Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Rilzabrutinib Estradiol Transdermal Patch Alora® Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Rilzabrutinib Everolimus Afinitor Increased P-gp substrate with NTI exposure and an increased risk of P-gp substrate with NTI-related adverse reactions Details Rilzabrutinib Felodipine Plendil® Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Rilzabrutinib Fentanyl Transdermal Patch Duragesic® Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Rilzabrutinib Finerenone Kerendia Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Rilzabrutinib Fostamatinib Tavalisse Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Rilzabrutinib Fostemsavir Rukobia Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Rilzabrutinib Futibatinib Lytgobi Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Rilzabrutinib Gilteritinib Xospata Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Rilzabrutinib Glasdegib Daurismo Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Rilzabrutinib Guanfacine Intuniv Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Rilzabrutinib Hydrocortisone Ala-Cort Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Rilzabrutinib Hydrocortisone Injection A-Hydrocort® Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Rilzabrutinib Ibrexafungerp Brexafemme Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Rilzabrutinib Ibrutinib Imbruvica Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Rilzabrutinib Ifosfamide Injection Ifex Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Rilzabrutinib Infigratinib Truseltiq Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Rilzabrutinib Irinotecan Camptosar Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Rilzabrutinib Irinotecan Injection Camptosar Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Rilzabrutinib Irinotecan Lipid Complex Injection Onivyde® Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Rilzabrutinib Istradefylline Nourianz Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details